404 related articles for article (PubMed ID: 19322070)
1. Combination effects of SC144 and cytotoxic anticancer agents.
Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
[TBL] [Abstract][Full Text] [Related]
2. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
3. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
5. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
[TBL] [Abstract][Full Text] [Related]
6. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
7. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
8. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
[TBL] [Abstract][Full Text] [Related]
9. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
van Iersel LB; Koudijs TM; Hoekman EJ; Janssen-van Rhijn CM; Vahrmeijer AL; Nortier JW; van de Velde CJ; Gelderblom H; Kuppen PJ
J Surg Res; 2011 May; 167(2):273-8. PubMed ID: 20036390
[TBL] [Abstract][Full Text] [Related]
10. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity.
Plasencia C; Grande F; Oshima T; Cao X; Yamada R; Sanchez T; Aiello F; Garofalo A; Neamati N
Cancer Biol Ther; 2009 Mar; 8(5):458-65. PubMed ID: 19221468
[TBL] [Abstract][Full Text] [Related]
16. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
17. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity of HO-221, a derivative of benzoylphenylurea against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2255-61. PubMed ID: 1929446
[TBL] [Abstract][Full Text] [Related]
19. In vitro histoculture drug response assay and in vivo blood chemistry of a novel Pt(IV) compound, K104.
Kwon YE; Park JY; Kim WK
Anticancer Res; 2007; 27(1A):321-6. PubMed ID: 17352249
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]